| Year |
Citation |
Score |
| 2024 |
Sentana-Lledo D, Chu X, Jarrard DF, Carducci MA, DiPaola RS, Wagner LI, Cella D, Sweeney CJ, Morgans AK. Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED). European Urology Oncology. PMID 38688766 DOI: 10.1016/j.euo.2024.04.010 |
0.374 |
|
| 2023 |
Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, Buckley DI, Griffin JC, Cookson MS. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). The Journal of Urology. 101097JU000000000000. PMID 37096583 DOI: 10.1097/JU.0000000000003452 |
0.439 |
|
| 2023 |
Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, et al. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. Journal of the National Comprehensive Cancer Network : Jnccn. 21: 236-246. PMID 36898362 DOI: 10.6004/jnccn.2023.0014 |
0.429 |
|
| 2023 |
Yu YP, Liu S, Ren BG, Nelson J, Jarrard D, Brooks JD, Michalopoulos G, Tseng G, Luo JH. Fusion gene detection in prostate cancer samples enhances the prediction of prostate cancer clinical outcomes from radical prostatectomy through machine learning in a multi- institutional analysis. The American Journal of Pathology. PMID 36681188 DOI: 10.1016/j.ajpath.2022.12.013 |
0.48 |
|
| 2022 |
Rodems TS, Heninger E, Stahlfeld CN, Gilsdorf CS, Carlson KN, Kircher MR, Singh A, Krueger TEG, Beebe DJ, Jarrard DF, McNeel DG, Haffner MC, Lang JM. Reversible epigenetic alterations regulate class I HLA loss in prostate cancer. Communications Biology. 5: 897. PMID 36050516 DOI: 10.1038/s42003-022-03843-6 |
0.41 |
|
| 2022 |
Filon MJ, Gillette AA, Yang B, Khemees TA, Skala MC, Jarrard DF. Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy. The Prostate. PMID 35980831 DOI: 10.1002/pros.24428 |
0.425 |
|
| 2022 |
Morgans AK, Chen YH, Jarrard DF, Carducci M, Liu G, Eisenberger M, Plimack ER, Bryce A, Garcia JA, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, DiPaola RS, et al. Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. The Prostate. PMID 35538398 DOI: 10.1002/pros.24369 |
0.42 |
|
| 2022 |
Vitek RA, Huang W, Geiger PG, Heninger E, Lang JM, Jarrard DF, Beebe DJ, Johnson BP. Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment. The Prostate. PMID 35226381 DOI: 10.1002/pros.24326 |
0.356 |
|
| 2021 |
Khemees TA, Yang B, Schultz A, Allen GO, Gawdzik J, Nihal A, Richards KA, Abel EJ, Jarrard DF. Epigenetic field alterations in non-tumor prostate tissues detect prostate cancer in urine. American Journal of Clinical and Experimental Urology. 9: 479-488. PMID 34993267 |
0.45 |
|
| 2021 |
Heninger E, Kosoff D, Rodems TS, Sethakorn N, Singh A, Gungurthi H, Carlson KN, Yang B, Gilsdorf C, Pasch CA, Deming DA, Ellis L, Beebe DJ, Jarrard DF, Lang JM. Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling. Medical Oncology (Northwood, London, England). 38: 135. PMID 34581895 DOI: 10.1007/s12032-021-01582-y |
0.368 |
|
| 2021 |
Filon M, Gawdzik J, Truong A, Allen G, Huang W, Khemees T, Machhi R, Lewis P, Yang B, Denu J, Jarrard D. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype. British Journal of Cancer. PMID 33976366 DOI: 10.1038/s41416-021-01398-7 |
0.429 |
|
| 2021 |
Posielski NM, Richards KA, Liou JI, Borza T, Abel EJ, Downs TM, Jarrard DF. Beta-Adrenergic Antagonists and Cancer Specific Survival in Patients with Advanced Prostate Cancer: A Veterans Administration Cohort Study. Urology. PMID 33587939 DOI: 10.1016/j.urology.2021.02.008 |
0.426 |
|
| 2020 |
Luo JH, Liu S, Tao J, Ren BG, Luo K, Chen ZH, Nalesnik M, Cieply K, Ma T, Cheng SY, Chen Q, Michalopoulos GK, Nelson JB, Bhargava R, Zhang J, ... ... Jarrard D, et al. Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings. Oncogene. PMID 33323972 DOI: 10.1038/s41388-020-01582-8 |
0.327 |
|
| 2020 |
Jarrard D, Filon M, Huang W, Havighurst T, DeShong K, Kim K, Konety BR, Saltzstein D, Mukhtar H, Wollmer B, Suen C, House MG, Parnes HL, Bailey HH. A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance. The Prostate. PMID 33095939 DOI: 10.1002/pros.24076 |
0.439 |
|
| 2020 |
Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. The Journal of Urology. 101097JU000000000000. PMID 32960679 DOI: 10.1097/JU.0000000000001375 |
0.462 |
|
| 2020 |
Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. The Journal of Urology. 101097JU000000000000. PMID 32960678 DOI: 10.1097/JU.0000000000001376 |
0.453 |
|
| 2020 |
Yang B, Damodaran S, Khemees TA, Filon MJ, Schultz A, Gawdzik J, Etheridge T, Malin D, Richards KA, Cryns VL, Jarrard DF. Synthetic Lethal Metabolic Targeting of Androgen Deprived Prostate Cancer Cells with Metformin. Molecular Cancer Therapeutics. PMID 32943543 DOI: 10.1158/1535-7163.Mct-19-1141 |
0.495 |
|
| 2020 |
Damaschke NA, Gawdzik J, Avilla M, Yang B, Svaren J, Roopra A, Luo JH, Yu YP, Keles S, Jarrard DF. CTCF loss mediates unique DNA hypermethylation landscapes in human cancers. Clinical Epigenetics. 12: 80. PMID 32503656 DOI: 10.1186/S13148-020-00869-7 |
0.331 |
|
| 2020 |
Hearn JWD, Sweeney CJ, Almassi N, Reichard CA, Reddy CA, Li H, Hobbs B, Jarrard DF, Chen YH, Dreicer R, Garcia JA, Carducci MA, DiPaola RS, Sharifi N. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Jama Oncology. e196496. PMID 32053149 DOI: 10.1001/Jamaoncol.2019.6496 |
0.404 |
|
| 2020 |
Sethakorn N, Kosoff D, Heninger E, Soto JM, Yu J, Das R, Jarrard D, Galipeau J, Hematti P, Dehm S, Beebe DJ, Lang JM. Abstract B24: A multicellular, microfluidic model of the human bone marrow niche in metastatic cancers Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-B24 |
0.387 |
|
| 2020 |
Khemees TA, Kyriakopoulos CE, Cho SY, Johnson B, Roldán-Alzate A, Huang W, Beebe DJ, Emamekhoo H, Wells S, Lang JM, Jarrard DF. Mp79-11 Feasibility Of Consolidative Surgery In Oligometastatic And Locally Advanced Prostate Cancer: Initial Surgical Results From Phase Ii Trial Of Neoadjuvant Therapy And Psma Pet/Mri Imaging The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000971.011 |
0.436 |
|
| 2020 |
Filon* M, Gawdzik J, Truong A, Yang B, Machhi R, Jarrard DF. PD52-07 TANDEM HISTONE METHYLTRANSFERASE UPREGULATION DEFINES A UNIQUE AGGRESSIVE PROSTATE CANCER PHENOTYPE The Journal of Urology. 203: e1092. DOI: 10.1097/Ju.0000000000000954.07 |
0.493 |
|
| 2020 |
Khemees* TA, Filon M, Yang B, Gillette A, Gawdzik J, Showalter M, Fiehn O, Skala M, Jarrard DF. MP51-11 ANDROGEN DEPRIVATION THERAPY INDUCES UNIQUE ANTI-WARBURG METABOLIC ALTERATION IN HORMONE SENSITIVE PROSTATE CANCER CELLS The Journal of Urology. 203: e767-e768. DOI: 10.1097/Ju.0000000000000913.011 |
0.527 |
|
| 2020 |
Filon* M, Khemees TA, Yang B, Gillette A, Luckey A, Skala M, Jarrard DF. MP16-16 PROSTATE CANCER CELLS AFTER ANDROGEN DEPRIVATION THERAPY DEMONSTRATE UNIQUE SUBSTRATE ADAPTABILITY IN THE SETTING OF METABOLIC INHIBITION The Journal of Urology. 203: e221-e222. DOI: 10.1097/Ju.0000000000000841.016 |
0.463 |
|
| 2019 |
Yang B, Etheridge T, McCormick J, Schultz A, Khemees TA, Damaschke N, Leverson G, Woo K, Sonn GA, Klein EA, Fumo M, Huang W, Jarrard DF. Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies. Clinical Epigenetics. 11: 168. PMID 31779677 DOI: 10.1186/S13148-019-0771-5 |
0.573 |
|
| 2019 |
Rutkowski DR, Wells SA, Johnson B, Huang W, Jarrard DF, Lang JM, Cho S, Roldán-Alzate A. Mri-based cancer lesion analysis with 3d printed patient specific prostate cutting guides. American Journal of Clinical and Experimental Urology. 7: 215-222. PMID 31511828 |
0.427 |
|
| 2019 |
Yu J, Berthier E, Craig A, de Groot TE, Sparks S, Ingram PN, Jarrard DF, Huang W, Beebe DJ, Theberge AB. Reconfigurable open microfluidics for studying the spatiotemporal dynamics of paracrine signalling. Nature Biomedical Engineering. PMID 31427781 DOI: 10.1038/S41551-019-0421-4 |
0.315 |
|
| 2019 |
Jarrard WE, Schultz A, Etheridge T, Damodaran S, Allen GO, Jarrard D, Yang B. Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection. Plos One. 14: e0218950. PMID 31233548 DOI: 10.1371/Journal.Pone.0218950 |
0.555 |
|
| 2019 |
Wang JH, Sierra P, Richards KA, Abel EJ, Allen GO, Downs TM, Jarrard DF. Impact of bilateral biopsy-detected prostate cancer on an active surveillance population. Bmc Urology. 19: 26. PMID 31014300 DOI: 10.1186/S12894-019-0452-X |
0.537 |
|
| 2019 |
Etheridge T, Damodaran S, Schultz A, Richards KA, Gawdzik J, Yang B, Cryns V, Jarrard DF. Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier. Asian Journal of Urology. 6: 57-64. PMID 30775249 DOI: 10.1016/J.Ajur.2018.09.001 |
0.518 |
|
| 2019 |
Damodaran S, Lang JM, Jarrard DF. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches. The Journal of Urology. PMID 30747897 DOI: 10.1097/Ju.0000000000000117 |
0.548 |
|
| 2019 |
Etheridge T, Schultz A, McCormick J, Damodaran S, Yang* B, Allen GO, Huang W, LaViolette P, Jarrard D. MP81-20 AUTOMATED IMAGE ANALYSIS OF HISTOLOGICALLY BENIGN PROSTATE BIOPSIES PREDICTS CANCER PRESENCE Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557439.15646.Cd |
0.519 |
|
| 2019 |
Gawdzik J, Yang* B, Machhi R, Roopra A, Khemees T, Jarrard D. MP68-08 A ‘BROKEN CTCF’ GENE SIGNATURE, A MASTER EPIGENETIC REGULATOR, PREDICTS ADVERSE CANCER OUTCOME AND ALTERED AMINO ACID TRANSPORT IN PROSTATE CANCER. Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557023.64212.7C |
0.495 |
|
| 2019 |
Etheridge T, Liou J, Downs TM, Abel EJ, Jarrard DF, Richards KA. Mp41-01 The Impact Of Agent Orange Exposure On Prostate Cancer Outcomes The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556114.43093.A4 |
0.524 |
|
| 2019 |
Khemees TA, Liou J, Abel EJ, Downs TM, Borza T, Jarrard DF, Richards KA. Pd25-05 Understanding The Role Of Statin Use On Advanced Prostate Cancer Outcomes: Does The Statin Type, Cumulative Dose Or Duration Impact Survival? The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555940.45652.95 |
0.44 |
|
| 2019 |
Khemees TA, Yang B, Schultz A, Allen GO, Gawdzik J, Richards KA, Downs TM, Abel EJ, Jarrard DF. Pd11-05 Epigenetic Field Alterations In Non-Tumor Prostate Tissues Can Detect Prostate Cancer In Urine The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555361.67170.Df |
0.525 |
|
| 2019 |
Khemees* TA, Yang B, Schultz A, Etheridge T, Leverson G, Sonn G, Magi-Galluzzi C, Klein EA, Fumo MJ, Jarrard DF. PD05-07 EPIGENETIC METHYLATION DIFFERENCES DISPLAY MORE VARIATION IN TUMOR-ASSOCIATED VERSUS NON-TUMOR ASSOCIATED BENIGN PROSTATE TISSUES: THE FIELD DEFECT HYPOTHESIS Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555067.78790.4A |
0.526 |
|
| 2018 |
Anderson-Carter I, Posielski N, Liou JI, Khemees TA, Downs TM, Abel EJ, Jarrard DF, Richards KA. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study. Urologic Oncology. PMID 30528885 DOI: 10.1016/J.Urolonc.2018.11.017 |
0.555 |
|
| 2018 |
Etheridge T, Straus J, Ritter MA, Jarrard DF, Huang W. Semen AMACR protein as a novel method for detecting prostate cancer. Urologic Oncology. PMID 30337219 DOI: 10.1016/J.Urolonc.2018.09.010 |
0.529 |
|
| 2018 |
Etheridge T, Liou JI, Downs TM, Abel EJ, Jarrard DF, Richards KA. The Impact of Agent Orange Exposure on Prostate Cancer Outcomes. The Journal of Urology. PMID 30321553 DOI: 10.1016/J.Juro.2018.10.005 |
0.54 |
|
| 2018 |
Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. The Journal of Urology. PMID 30086276 DOI: 10.1016/j.juro.2018.07.090 |
0.442 |
|
| 2018 |
Etheridge T, Liou J, Downs TM, Abel EJ, Richards KA, Jarrard DF. The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy. American Journal of Clinical and Experimental Urology. 6: 123-132. PMID 30038944 |
0.346 |
|
| 2018 |
Richards KA, Liou JI, Cryns VL, Downs TM, Abel EJ, Jarrard DF. Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. The Journal of Urology. PMID 29940252 DOI: 10.1016/J.Juro.2018.06.031 |
0.451 |
|
| 2018 |
Maciolek KA, Best SL, Lopez V, Posielski N, Knoedler M, Bushman WA, Jarrard DF, Downs TM, Abel EJ, Richards KA. Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort. Urologic Oncology. PMID 29887242 DOI: 10.1016/J.Urolonc.2018.05.009 |
0.419 |
|
| 2018 |
Cesnik AJ, Yang B, Truong A, Etheridge T, Spiniello M, Steinbrink MI, Shortreed MR, Frey BL, Jarrard DF, Smith LM. Long Noncoding RNAs AC009014.3 and Newly Discovered XPLAID Differentiate Aggressive and Indolent Prostate Cancers. Translational Oncology. 11: 808-814. PMID 29723810 DOI: 10.1016/J.Tranon.2018.04.002 |
0.492 |
|
| 2018 |
Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017753335. PMID 29522362 DOI: 10.1200/Jco.2017.75.3335 |
0.409 |
|
| 2018 |
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017753657. PMID 29384722 DOI: 10.1200/Jco.2017.75.3657 |
0.455 |
|
| 2018 |
Johnson BP, Vitek RA, Geiger PG, Huang W, Jarrard DF, Lang JM, Beebe DJ. Vital ex vivo tissue labeling and pathology-guided micropunching to characterize cellular heterogeneity in the tissue microenvironment. Biotechniques. 64: 13-19. PMID 29384072 DOI: 10.2144/000114626 |
0.362 |
|
| 2018 |
Sierra PS, Damodaran S, Jarrard D. Clinical and pathologic factors predicting reclassification in active surveillance cohorts. International Braz J Urol. 44: 440-451. PMID 29368876 DOI: 10.1590/S1677-5538.Ibju.2017.0320 |
0.403 |
|
| 2018 |
Damodaran S, Gettle LM, Frederick K, Allen GO, Richards k, Abel EJ, Downs T, Jarrard D. Mp20-08 Mr Imaging Of Prostate Cancer Shows Reduced Enhancement Kinetic Curves In Men On 5-Alpha Reductase Inhibitors With Implications For Cancer Detection The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.678 |
0.503 |
|
| 2018 |
Posielski N, Anderson-Carter I, Liou J, Abel EJ, Downs T, Jarrard D, Richards K. Mp87-15 Use Of Statins In Combination With Androgen Deprivation Therapy In Patients With Advanced Prostate Cancer: Impact On Oncological Outcomes. The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2915 |
0.521 |
|
| 2018 |
Truong A, Roberge G, Liou J, Abel EJ, Downs T, Jarrard D, Richards K. Mp87-12 The Impact Of Metformin Use On Oncologic Outcomes In Prostate Cancer Patients Receiving Docetaxel Chemotherapy The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2912 |
0.516 |
|
| 2018 |
Cesnik AJ, Truong AV, Etheridge T, Yang B, Spiniello M, Steinbrink MI, Shortreed MR, Frey BL, Allen GO, Jarrard DF, Smith LM. Pd60-09 Discovery And Validation Of Novel Long Noncoding Rnas That Differentiate Aggressive And Indolent Prostate Cancer The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2821 |
0.457 |
|
| 2017 |
Damodaran S, Damaschke N, Gawdzik J, Yang B, Shi C, Allen GO, Huang W, Denu J, Jarrard D. Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes. Bmc Cancer. 17: 874. PMID 29262808 DOI: 10.1186/S12885-017-3853-9 |
0.507 |
|
| 2017 |
Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, et al. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone Sensitive Prostate Cancer Treated With Androgen Deprivation With Or Without Docetaxel. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017753921. PMID 29261442 DOI: 10.1200/Jco.2017.75.3921 |
0.499 |
|
| 2017 |
Damodaran S, Kyriakopoulos CE, Jarrard DF. Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed? The Urologic Clinics of North America. 44: 611-621. PMID 29107277 DOI: 10.1016/J.Ucl.2017.07.008 |
0.553 |
|
| 2017 |
Lee JH, Yang B, Lindahl AJ, Damaschke N, Boersma MD, Huang W, Corey E, Jarrard DF, Denu JM. Identifying dysregulated epigenetic enzyme activity in castrate-resistant prostate cancer development. Acs Chemical Biology. PMID 28949514 DOI: 10.1021/Acschembio.6B01035 |
0.388 |
|
| 2017 |
Maciolek KA, Jarrard DF, Abel EJ, Best SL. Systematic Assessment Reveals Lack of Understandability for Prostate Biopsy Online Patient Education Materials. Urology. PMID 28780302 DOI: 10.1016/J.Urology.2017.07.037 |
0.425 |
|
| 2017 |
Damaschke N, Yang B, Bhusari S, Avilla M, Zhong W, Blute ML, Huang W, Jarrard DF. Loss of IGF2 gene imprinting in murine prostate promotes widespread neoplastic growth. Cancer Research. PMID 28775169 DOI: 10.1158/0008-5472.Can-16-3089 |
0.515 |
|
| 2017 |
Wang JH, Downs TM, Jason Abel E, Richards KA, Jarrard DF. Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies. Current Urology Reports. 18: 48. PMID 28589399 DOI: 10.1007/S11934-017-0702-Y |
0.535 |
|
| 2017 |
Blute ML, Damaschke N, Wagner J, Yang B, Gleave M, Fazli L, Shi F, Abel EJ, Downs TM, Huang W, Jarrard DF. Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. Plos One. 12: e0172048. PMID 28234906 DOI: 10.1371/Journal.Pone.0172048 |
0.434 |
|
| 2017 |
Lee J, Boersma M, Yang B, Damaschke N, Corey E, Denu J, Jarrard DF. Abstract 5389: A personalized medicine approach to identifying dysregulated epigenetic enzyme activity in the development of castrate-resistant prostate cancer Cancer Research. 77: 5389-5389. DOI: 10.1158/1538-7445.Am2017-5389 |
0.435 |
|
| 2017 |
Yang B, McCormick J, Schultz A, Leverson G, Sonn G, Magi-Galluzi C, Klein EA, Fumo M, Jarrard DF. Abstract 2390: Clinical validation of an epigenetic field of susceptibility to detect significant prostate cancer from 2 non-tumor biopsies Cancer Research. 77: 2390-2390. DOI: 10.1158/1538-7445.Am2017-2390 |
0.591 |
|
| 2017 |
Maciolek KA, Best SL, Bushman WA, Jarrard DF, Downs TM, Abel EJ, Richards KA. Mp77-05 Simple Prostate Biopsy Protocol With Augmented Antibiotics Decreases Complications And Admissions In Veterans The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2113 |
0.466 |
|
| 2017 |
Richards K, Liou J, Cryns V, Downs T, Abel J, Jarrard D. MP53-08 METFORMIN USE IS ASSOCIATED WITH IMPROVED SURVIVAL IN VETERANS WITH ADVANCED PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1659 |
0.535 |
|
| 2017 |
Jarrard D, Chen Y, Liu G, Carducci M, Eisenberger M, Wong Y, Hahn N, Kohli M, Cooney M, Dreicer R, Vogelzang N, Picus J, Shevrin D, Hussain M, Garcia J, et al. Mp53-07 Impact Of Metformin On Prostate Cancer Pc Outcomes In The E3805 Chaarted Trial The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1658 |
0.496 |
|
| 2017 |
Downs TM, Rushmer TJ, Abel EJ, Damodaran S, Richards KA, Jarrard DF. Diabetic Metrics That Lead to Increased Recurrence Rates in Non-Muscle Invasive Bladder Cancer Journal of the American College of Surgeons. 225. DOI: 10.1016/J.Jamcollsurg.2017.07.653 |
0.306 |
|
| 2016 |
Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR, Kosoff D, Yang B, Jarrard DF, McNeel DG, Lang JM. Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget. PMID 27769045 DOI: 10.18632/Oncotarget.12711 |
0.456 |
|
| 2016 |
Jarrard D, Konety B, Huang W, Downs T, Kolesar J, Kim KM, Havighurst T, Slaton J, House MG, Parnes HL, Bailey HH. Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. American Journal of Clinical and Experimental Urology. 4: 17-27. PMID 27766277 |
0.383 |
|
| 2016 |
Blute ML, Shiau JM, Truong M, Shi F, Abel EJ, Downs TM, Jarrard DF. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. World Journal of Urology. PMID 27631325 DOI: 10.1007/S00345-016-1933-0 |
0.506 |
|
| 2016 |
Kelcz F, Jarrard DF. Prostate cancer: The applicability of textural analysis of MRI for grading. Nature Reviews. Urology. 13: 185-6. PMID 26878802 DOI: 10.1038/Nrurol.2016.33 |
0.436 |
|
| 2016 |
Damaschke NA, Yang B, Montgomery A, Svaren J, Roopra A, Luo J, Keles S, Jarrard D. Abstract 4434: CTCF acts as a master regulator to direct epigenetic events important for tumor development and progression Cancer Research. 76: 4434-4434. DOI: 10.1158/1538-7445.Am2016-4434 |
0.508 |
|
| 2016 |
Yang B, McCormick J, Damaschke N, Montgomery A, Leverson G, Huang W, Lin DW, Jarrard DF. Abstract 4341: Employing the epigenetic field effect to detect prostate cancer in biopsy-negative patients Cancer Research. 76: 4341-4341. DOI: 10.1158/1538-7445.Am2016-4341 |
0.531 |
|
| 2016 |
Grimes MD, Blute ML, Mann MA, Downs TM, Shi F, Jarrard DF, Best SL, Richards KA, Nakada SY, Abel EJ. MP64-15 A CRITICAL ANALYSIS OF POSTOPERATIVE MORBIDITY IN MORBIDLY OBESE PATIENTS FOLLOWING RENAL CANCER SURGERY Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.965 |
0.305 |
|
| 2016 |
McCormick JR, Blute ML, Yang B, Damaschke N, Jarrard DF. MP50-05 SYNTHETIC LETHAL METABOLIC TARGETING OF CELLULAR SENESCENCE IN PROSTATE CANCER WITH THE REPURPOSED DRUG METFORMIN Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.439 |
0.494 |
|
| 2016 |
Blute ML, Kucherov V, Shapiro DD, Rushmer TJ, Shi F, Fuller B, Richards KA, Abel EJ, Jarrard DF, Messing EM, Downs TM. MP13-12 MODERATE CHRONIC KIDNEY DISEASE (EGFR <60 ML/MIN) PREDICTS RECURRENCE AND PROGRESSION IN BLADDER CANCER PATIENTS TREATED WITH TRANSURETHRAL RESECTION Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2493 |
0.341 |
|
| 2016 |
Jarrard DF, Konety BR, Slaton J, Huang W, Downs T, Kolesar J, Kim K, Havighurst T, House MG, Parnes HL, Bailey HH. MP04-14 PHASE IIA, RANDOMIZED PLACEBO-CONTROLLED TRIAL OF SINGLE HIGH DOSE CHOLECALCIFEROL (VITAMIN D
3
) AND DAILY GENISTEIN (G-2535) VERSUS PLACEBO IN MEN WITH EARLY STAGE PROSTATE CANCER UNDERGOING PROSTATECTOMY Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1949 |
0.412 |
|
| 2015 |
Jarrard DF, Huang W. The New Age of Molecular Taxonomy Approaches. European Urology. PMID 26626616 DOI: 10.1016/J.Eururo.2015.11.011 |
0.512 |
|
| 2015 |
Blute ML, Zorn K, Grimes M, Shi F, Downs TM, Jarrard DF, Best SL, Richards K, Nakada SY, Abel EJ. Extreme Obesity Does Not Predict Poor Cancer Outcomes Following Surgery for Renal Cell Cancer. Bju International. PMID 26589741 DOI: 10.1111/Bju.13381 |
0.354 |
|
| 2015 |
Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, Havighurst TC, Harris L, Wollmer BW, Jarrard D, House M, Parnes H, Bailey HH. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (Ecp). PMID 26313229 DOI: 10.1097/Cej.0000000000000189 |
0.55 |
|
| 2015 |
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England Journal of Medicine. PMID 26244877 DOI: 10.1056/Nejmoa1503747 |
0.495 |
|
| 2015 |
Blute ML, Rushmer TJ, Shi F, Fuller B, Abel EJ, Jarrard DF, Downs TM. Renin-Angiotensin Inhibitors Decrease Recurrence After Turbt in Non-Muscle Invasive Bladder Cancer. The Journal of Urology. PMID 26173101 DOI: 10.1016/J.Juro.2015.05.104 |
0.379 |
|
| 2015 |
Blute ML, Abel EJ, Downs TM, Kelcz F, Jarrard DF. Addressing the need for repeat prostate biopsy: New technology and approaches Nature Reviews Urology. 12: 435-444. PMID 26171803 DOI: 10.1038/Nrurol.2015.159 |
0.551 |
|
| 2015 |
Wagner J, Damaschke N, Yang B, Truong M, Guenther C, McCormick J, Huang W, Jarrard D. Overexpression of the novel senescence marker β-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence. Plos One. 10: e0124366. PMID 25876105 DOI: 10.1371/Journal.Pone.0124366 |
0.44 |
|
| 2015 |
Blute ML, Damaschke NA, Jarrard DF. The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications. Current Opinion in Urology. 25: 83-8. PMID 25405932 DOI: 10.1097/Mou.0000000000000132 |
0.516 |
|
| 2015 |
Heninger E, Krueger T, Johnson B, Sperger J, Jarrard D, Lang J. Inducible expression of antigen processing and antigen presentation molecules and cancer testis antigens in human prostate cancer Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P224 |
0.558 |
|
| 2015 |
Blute ML, Yang B, Damaschke N, Lamming D, Hoffman FM, Jarrard DF. MP55-11 SYNTHETIC LETHAL METABOLIC TARGETING OF CELLULAR SENESCENCE IN PROSTATE CANCER WITH METFORMIN Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2054 |
0.351 |
|
| 2015 |
Blute ML, Wagner J, Damaschke N, Yang B, Gleave M, Fazli L, Huang W, Jarrard DF. MP37-20 NEOADJUVANT ANDROGEN DEPRIVATION THERAPY INDUCES SENESCENCE IN RADICAL PROSTATECTOMY SPECIMENS Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1283 |
0.451 |
|
| 2015 |
Blute ML, Rushmer TJ, Shi F, Fuller B, Abel EJ, Jarrard DF, Downs TM. Mp26-09 Moderate Chronic Kidney Disease (Egfr < 60 Ml/Min) Predicts Recurrence And Progression In Bladder Cancer Patients Treated With Transurethral Resection The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1131 |
0.341 |
|
| 2015 |
Blute ML, Rushmer TJ, Shi F, Fuller B, Abel EJ, Jarrard DF, Downs TM. Mp26-08 Renin-Angiotensin Inhibitors Decrease Recurrence After Turbt In Non-Muscle Invasive Bladder Cancer The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1130 |
0.334 |
|
| 2015 |
Abel EJ, Blute ML, Downs TM, Grimes M, Zorn K, Jarrard DF, Best SL, Hedican SP, Nakada SY. Morbid obesity is not associated with worse outcomes following surgery for renal cell cancer (RCC) Journal of the American College of Surgeons. 221: e39. DOI: 10.1016/J.Jamcollsurg.2015.08.402 |
0.31 |
|
| 2015 |
Wojcieszynski AP, Jarrard DF, Graf AK, Saha S, Kruser TJ, Ritter MA. Long-term Efficacy and Toxicity of Hypofractionated Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.1024 |
0.485 |
|
| 2014 |
Chen YH, Carducci MA, Liu G, Jarrard DF, Eisenberger MA, Wong YN, Hahn NM, Kohli M, Vogelzang NJ, Cooney MM, Dreicer R, Picus J, Shevrin DH, Hussain M, Garcia JA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: LBA2. PMID 28141982 DOI: 10.1200/Jco.2014.32.18_Suppl.Lba2 |
0.419 |
|
| 2014 |
Damaschke NA, Yang B, Blute ML, Lin CP, Huang W, Jarrard DF. Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionally associated chromatin regulators in prostate cancer. Neoplasia (New York, N.Y.). 16: 1018-27. PMID 25499215 DOI: 10.1016/J.Neo.2014.10.003 |
0.506 |
|
| 2014 |
Keil KP, Abler LL, Laporta J, Altmann HM, Yang B, Jarrard DF, Hernandez LL, Vezina CM. Androgen receptor DNA methylation regulates the timing and androgen sensitivity of mouse prostate ductal development. Developmental Biology. 396: 237-45. PMID 25446526 DOI: 10.1016/J.Ydbio.2014.10.006 |
0.503 |
|
| 2014 |
Jarrard DF, Blute ML, Ritter MA. Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3926-9. PMID 25332250 DOI: 10.1200/Jco.2014.57.8302 |
0.463 |
|
| 2014 |
Yu YP, Ding Y, Chen Z, Liu S, Michalopoulos A, Chen R, Gulzar ZG, Yang B, Cieply KM, Luvison A, Ren BG, Brooks JD, Jarrard D, Nelson JB, Michalopoulos GK, et al. Novel fusion transcripts associate with progressive prostate cancer. The American Journal of Pathology. 184: 2840-9. PMID 25238935 DOI: 10.1016/J.Ajpath.2014.06.025 |
0.505 |
|
| 2014 |
Yang B, Wagner J, Damaschke N, Yao T, Wuerzberger-Davis SM, Lee MH, Svaren J, Miyamoto S, Jarrard DF. A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation. Plos One. 9: e88052. PMID 24558376 DOI: 10.1371/Journal.Pone.0088052 |
0.368 |
|
| 2014 |
Slawin KM, Ellis WJ, Tenke P, Joniau S, Alekseev BY, Buzogány I, Mishugin S, Klein EA, Karnes RJ, Scherr D, Yuh BE, Jarrard DF, Trabulsi EJ, Stolz J, Babich J, et al. A phase II study of 99mTc-trofolastat (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An interim analysis. Journal of Clinical Oncology. 32: 94-94. DOI: 10.1200/Jco.2014.32.4_Suppl.94 |
0.452 |
|
| 2014 |
Slawin KM, Tenke P, Joniau S, Ellis WJ, Alekseev BY, Buzogány I, Mishugin S, Klein EA, Stolz J, Student V, Matveev V, Karnes RJ, Jarrard DF, Yuh BE, Scherr D, et al. A phase 2 study of 99m Tc-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection compared to histopathology: An interim analysis. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E16003 |
0.439 |
|
| 2014 |
Damaschke N, Huang W, Lin CP, Lee JH, Jarrard D. MP52-03 DISRUPTION OF CHD8-CTCF CHROMATIN COMPLEX IN PROSTATE CANCER ALTERS DNA METHYLATION PATTERNS Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1613 |
0.48 |
|
| 2014 |
Allen H, Abel EJ, Shapiro DD, Shi F, Potretzke A, Jarrard DF, Ziemiewicz TJ, Downs TM. MP39-02 CORE MUSCLE SIZE PREDICTS 6-MONTH MORTALITY IN PATIENTS UNDERGOING RADICAL CYSTECTOMY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1317 |
0.324 |
|
| 2014 |
Rice S, Mohindra P, McHaffie DR, Jarrard DF, Graf AK, Adkison J, Ritter MA. Long Term Outcomes with Hypofractionated Radiotherapy (HFRT) for Clinically Localized Prostate Cancer: 70 Gy at 2.5 Gy per Fraction International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.190 |
0.478 |
|
| 2013 |
Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ, Downs TM, Jarrard DF. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 119: 3992-4002. PMID 24006289 DOI: 10.1002/Cncr.28303 |
0.508 |
|
| 2013 |
Damaschke NA, Yang B, Bhusari S, Svaren JP, Jarrard DF. Epigenetic susceptibility factors for prostate cancer with aging. The Prostate. 73: 1721-30. PMID 23999928 DOI: 10.1002/Pros.22716 |
0.561 |
|
| 2013 |
Yang B, Wagner J, Yao T, Damaschke N, Jarrard DF. Pyrosequencing for the rapid and efficient quantification of allele-specific expression. Epigenetics. 8: 1039-42. PMID 23973940 DOI: 10.4161/Epi.25892 |
0.333 |
|
| 2013 |
Yang B, Bhusari S, Kueck J, Weeratunga P, Wagner J, Leverson G, Huang W, Jarrard DF. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia (New York, N.Y.). 15: 399-408. PMID 23555185 DOI: 10.1593/Neo.13280 |
0.512 |
|
| 2013 |
Slezak J, Truong M, Huang W, Jarrard D. HP1γ expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy. Bmc Cancer. 13: 148. PMID 23522301 DOI: 10.1186/1471-2407-13-148 |
0.55 |
|
| 2013 |
Truong M, Yang B, Wagner J, Desotelle J, Jarrard DF. Analysis of promoter non-CG methylation in prostate cancer. Epigenomics. 5: 65-71. PMID 23414321 DOI: 10.2217/Epi.12.67 |
0.774 |
|
| 2013 |
Gee J, Bailey H, Kim K, Kolesar J, Havighurst T, Tutsch KD, See W, Cohen MB, Street N, Levan L, Jarrard D, Wilding G. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. The Prostate. 73: 970-8. PMID 23335089 DOI: 10.1002/Pros.22644 |
0.523 |
|
| 2013 |
Desotelle J, Truong M, Ewald J, Weeratunga P, Yang B, Huang W, Jarrard D. CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer Journal of Urology. 189: 329-335. PMID 23174249 DOI: 10.1016/J.Juro.2012.08.188 |
0.828 |
|
| 2013 |
Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, Dhir R, Nelson J, Lin DW, Jarrard DF. Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. The Journal of Urology. 189: 2335-41. PMID 23159584 DOI: 10.1016/J.Juro.2012.11.074 |
0.534 |
|
| 2013 |
Babaian K, Truong M, Cetnar J, Cross DS, Shi F, Ritter MA, Jarrard DF. Analysis of urological procedures in men who died from prostate cancer using a population-based approach. Bju International. 111: E65-70. PMID 23130676 DOI: 10.1111/J.1464-410X.2012.11517.X |
0.505 |
|
| 2013 |
Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis. The Journal of Urology. 189: 422-9. PMID 23017522 DOI: 10.1016/J.Juro.2012.04.143 |
0.565 |
|
| 2013 |
Ewald JA, Desotelle JA, Church DR, Yang B, Huang W, Laurila TA, Jarrard DF. Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo Prostate. 73: 337-345. PMID 22911222 DOI: 10.1002/Pros.22571 |
0.798 |
|
| 2013 |
King AC, Livermore A, Laurila TA, Huang W, Jarrard DF. Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. Urologic Oncology. 31: 739-43. PMID 21816639 DOI: 10.1016/J.Urolonc.2011.06.011 |
0.491 |
|
| 2013 |
Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, Dhir R, Nelson J, Lin D, Jarrard D. 2132 EMPLOYING THE EPIGENETIC FIELD EFFECT TO DETECT PROSTATE CANCER IN BIOPSY-NEGATIVE PATIENTS Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2041 |
0.532 |
|
| 2013 |
Truong M, Slezak J, Huang W, Jarrard D. 201 HP1γ IS ELEVATED IN PROSTATE CANCER AND IS SUPERIOR TO GLEASON SCORE AS A PREDICTOR OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1581 |
0.556 |
|
| 2013 |
Abel EJ, Devon O, Shi F, Jarrard DF, Downs TM. Intraoperative blood transfusion is associated with worse cancer specific survival in patients undergoing radical cystectomy Journal of the American College of Surgeons. 217. DOI: 10.1016/J.Jamcollsurg.2013.07.348 |
0.354 |
|
| 2012 |
Ewald JA, Jarrard DF. Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer. Translational Oncology. 5: 278-87. PMID 22937180 DOI: 10.1593/Tlo.12181 |
0.498 |
|
| 2012 |
Truong M, Yang B, Wagner J, Kobayashi Y, Rajamanickam V, Brooks J, Jarrard DF. Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence. British Journal of Cancer. 107: 100-7. PMID 22596233 DOI: 10.1038/Bjc.2012.216 |
0.562 |
|
| 2012 |
Van Bogaert D, Hawkins R, Pingree S, Jarrard D. The Development of an eHealth tool suite for prostate cancer patients and their partners. The Journal of Supportive Oncology. 10: 202-8. PMID 22591675 DOI: 10.1016/j.suponc.2012.02.003 |
0.355 |
|
| 2012 |
Ewald JA, Jarrard DF. Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer Translational Oncology. 5: 278-287. DOI: 10.1593/tlo.12181 |
0.471 |
|
| 2012 |
Truong M, Babaian K, Cetnar J, Cross D, Shi F, Ritter M, Jarrard D. 766 PREDICTORS OF UROLOGICAL PROCEDURES IN MEN DYING FROM PROSTATE CANCER USING A POPULATION-BASED APPROACH Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.853 |
0.51 |
|
| 2012 |
Truong M, Yang B, Kobayashi Y, Brooks J, Jarrard D. 1315 Even-Skipped Homeobox 1 (Evx1) Is Frequently Hypermethylated In Prostate Cancer And Predicts Psa Recurrence The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1662 |
0.561 |
|
| 2012 |
McGetrick JJ, Downs TM, Sado M, Jarrard DF, Abel EJ. 82 SYMPTOMATIC PULMONARY EMBOLISM IN MAJOR UROLOGIC CANCER SURGERY Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.128 |
0.315 |
|
| 2011 |
Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, et al. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research (Philadelphia, Pa.). 4: 1761-9. PMID 21896650 DOI: 10.1158/1940-6207.Capr-10-0343 |
0.569 |
|
| 2011 |
Kruser TJ, Jarrard DF, Graf AK, Hedican SP, Paolone DR, Wegenke JD, Liu G, Geye HM, Ritter MA. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer. 117: 2629-36. PMID 21656740 DOI: 10.1002/Cncr.25824 |
0.417 |
|
| 2011 |
Bhusari S, Yang B, Kueck J, Huang W, Jarrard DF. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. The Prostate. 71: 1621-30. PMID 21432864 DOI: 10.1016/J.Juro.2011.02.1695 |
0.527 |
|
| 2011 |
Ewald J, Desotelle J, Church D, Laurila T, Jarrard D. 1445 ANDROGEN DEPRIVATION INDUCES A DELAYED SENESCENT PHENOTYPE IN PROSTATE CANCER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1358 |
0.817 |
|
| 2010 |
Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. Journal of the National Cancer Institute. 102: 1536-46. PMID 20858887 DOI: 10.1093/Jnci/Djq364 |
0.768 |
|
| 2010 |
Patel SR, Kaplon DM, Jarrard D. A technique for the management of a large median lobe in robot-assisted laparoscopic radical prostatectomy. Journal of Endourology. 24: 1899-1901. PMID 20858064 DOI: 10.1089/End.2010.0074 |
0.32 |
|
| 2010 |
Quann P, Jarrard DF, Huang W. Current prostate biopsy protocols cannot reliably identify patients for focal therapy: correlation of low-risk prostate cancer on biopsy with radical prostatectomy findings. International Journal of Clinical and Experimental Pathology. 3: 401-7. PMID 20490330 |
0.464 |
|
| 2010 |
Bhusari SS, Dobosy JR, Fu V, Almassi N, Oberley T, Jarrard DF. Superoxide dismutase 1 knockdown induces oxidative stress and DNA methylation loss in the prostate. Epigenetics : Official Journal of the Dna Methylation Society. 5: 402-9. PMID 20458166 DOI: 10.4161/Epi.5.5.11853 |
0.438 |
|
| 2010 |
Huang W, Jarrard D, Ritter M, Waknitz M, Straus J, Wilding G. Abstract 4630: Seminal AMACR protein: a non-invasive test in the detection of prostate cancer Cancer Research. 70: 4630-4630. DOI: 10.1158/1538-7445.Am10-4630 |
0.569 |
|
| 2010 |
Ewald J, Desotelle J, Hoffman FM, Jarrard D. 1185 SENESCENCE AS CYTOSTATIC THERAPY: DRUG-INDUCED SENESCENCE IN PROSTATE CANCER CELLS REQUIRES SKP2-REGULATED P27KIP1 EXPRESSION Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.686 |
0.534 |
|
| 2010 |
Jarrard D, Busari S, Dobosy J, Fu V, Almassi N, Oberley T. 1184 SUPEROXIDE DISMUTASE 1 KNOCKDOWN INDUCES OXIDATIVE STRESS AND LOSS OF DNA METHYLATION IN THE PROSTATE Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.685 |
0.418 |
|
| 2010 |
Yang B, Kueck J, Bhusari S, Huang W, Jarrard D. 1430 DEFINING THE FIELD DEFECT ASSOCIATED WITH PROSTATE CANCER DEVELOPMENT USING UNBIASED METHYLATION PROFILING Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1123 |
0.528 |
|
| 2009 |
Ewald JA, Peters N, Desotelle JA, Hoffmann FM, Jarrard DF. A high-throughput method to identify novel senescence-inducing compounds. Journal of Biomolecular Screening. 14: 853-8. PMID 19641224 DOI: 10.1177/1087057109340314 |
0.759 |
|
| 2009 |
Gee JR, Jarrard DF, Bruskewitz RC, Moon TD, Hedican SP, Leverson GE, Nakada SY, Messing EM. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. Bju International. 103: 736-9. PMID 19007364 DOI: 10.1111/J.1464-410X.2008.08123.X |
0.364 |
|
| 2009 |
Warren M, Twohig M, Pier T, Eickhoff J, Lin CY, Jarrard D, Huang W. Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society For Applied Immunohistochemistry. 17: 23-30. PMID 18813126 DOI: 10.1097/Pai.0B013E31817C3334 |
0.454 |
|
| 2008 |
Fu VX, Dobosy JR, Desotelle JA, Almassi N, Ewald JA, Srinivasan R, Berres M, Svaren J, Weindruch R, Jarrard DF. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Research. 68: 6797-802. PMID 18701505 DOI: 10.1158/0008-5472.Can-08-1714 |
0.81 |
|
| 2008 |
Dobosy JR, Fu VX, Desotelle JA, Srinivasan R, Kenowski ML, Almassi N, Weindruch R, Svaren J, Jarrard DF. A methyl-deficient diet modifies histone methylation and alters Igf2 and H19 repression in the prostate. The Prostate. 68: 1187-95. PMID 18459101 DOI: 10.1002/Pros.20782 |
0.783 |
|
| 2008 |
Ewald JA, Desotelle JA, Almassi N, Jarrard DF. Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo British Journal of Cancer. 98: 1244-1249. PMID 18349844 DOI: 10.1038/Sj.Bjc.6604288 |
0.791 |
|
| 2008 |
Wong GW, Palazzi-Churas KL, Jarrard DF, Paolone DR, Graf AK, Hedican SP, Wegenke JD, Ritter MA. Salvage Hypofractionated Radiotherapy for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy International Journal of Radiation Oncology Biology Physics. 70: 449-455. PMID 17869014 DOI: 10.1016/J.Ijrobp.2007.06.042 |
0.532 |
|
| 2008 |
Fu VX, Dobosy JR, Dosetelle JA, Almassi N, Ewald JA, Srinivasan R, Svaren J, Weindruch RH, Jarrard DF. AGING-RELATED LOSS OF INSULIN-LIKE GROWTH FACTOR-2 (Igf2) IMPRINTING IN THE PROSTATE Journal of Urology. 179: 394-394. DOI: 10.1016/S0022-5347(08)61154-4 |
0.412 |
|
| 2008 |
Ewald JA, Laurila T, Almassi N, Dosetelle JA, Jarrard DF. A NOVEL HIGH THROUGHPUT SCREEN IDENTIFIES POTENT SENESCENCE-INDUCING ACTIVITY OF DIAZIQUONE (AZQ) IN PROSTATE CANCER CELLS Journal of Urology. 179: 390-391. DOI: 10.1016/S0022-5347(08)61143-X |
0.526 |
|
| 2008 |
Laurila T, Ewald JA, Church DR, Almassi N, Jarrard DF. ANDROGEN ABLATION INDUCES SENESCENCE CHARACTERISTICS IN VIVO AND IN VITRO Journal of Urology. 179: 189-189. DOI: 10.1016/S0022-5347(08)60549-2 |
0.333 |
|
| 2008 |
Kibel AS, Eisenberger M, Picus J, Dreicer R, Klein EA, Roth B, Cookson MS, Wilding GE, Jarrard DF, Salavaggione L, Watson M. GENE EXPRESSION PROFILING FOR THE PREDICTION OF THERAPEUTIC RESPONSE TO ADJUVANT DOCETAXEL FOR HIGH RISK LOCALIZED PROSTATE CARCINOMA Journal of Urology. 179: 47-47. DOI: 10.1016/S0022-5347(08)60142-1 |
0.437 |
|
| 2007 |
Best S, Sawers Y, Fu VX, Almassi N, Huang W, Jarrard DF. Integrity of prostatic tissue for molecular analysis after robotic-assisted laparoscopic and open prostatectomy. Urology. 70: 328-32. PMID 17826499 DOI: 10.1016/J.Urology.2007.04.005 |
0.319 |
|
| 2007 |
Allen GW, Howard AR, Jarrard DF, Ritter MA. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer. 110: 1405-16. PMID 17685384 DOI: 10.1002/Cncr.22940 |
0.481 |
|
| 2007 |
Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. The Journal of Urology. 177: 1777-81. PMID 17437819 DOI: 10.1016/J.Juro.2007.01.028 |
0.412 |
|
| 2007 |
Katz DA, Jarrard DF, McHorney CA, Hillis SL, Wiebe DA, Fryback DG. Health perceptions in patients who undergo screening and workup for prostate cancer. Urology. 69: 215-20. PMID 17320653 DOI: 10.1016/J.Urology.2006.09.059 |
0.447 |
|
| 2007 |
Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. The Journal of Urology. 177: 822-31. PMID 17296351 DOI: 10.1016/J.Juro.2006.10.063 |
0.541 |
|
| 2006 |
Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman SM, Lieberman R, Alberts D, Jarrard D, Coltman C, Greenwald P, Minasian L, Crawford ED. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 15: 1479-84. PMID 16896036 DOI: 10.1158/1055-9965.Epi-05-0585 |
0.55 |
|
| 2006 |
Aziz MH, Nihal M, Fu VX, Jarrard DF, Ahmad N. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Molecular Cancer Therapeutics. 5: 1335-41. PMID 16731767 DOI: 10.1158/1535-7163.Mct-05-0526 |
0.497 |
|
| 2006 |
Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 15: 217-27. PMID 16492908 DOI: 10.1158/1055-9965.Epi-05-0737 |
0.488 |
|
| 2006 |
Ewald JA, Dobosy JA, Almassi N, Jarrard DF. 254: Biologic Effect of Senescent Prostate Cancer Cells in vitro and in vivo Journal of Urology. 175: 84-84. DOI: 10.1016/S0022-5347(18)32521-7 |
0.575 |
|
| 2006 |
Dobosy J, Fu V, Roberts JL, Desotelle JA, Almassi N, Weindruch R, Jarrard DF. 252: Methyl-Deficient Diet Leads to an Increase in Insulin-Like Growth Factor-2 (IGF2) Expression in the Prostate Journal of Urology. 175: 83-84. DOI: 10.1016/S0022-5347(18)32519-9 |
0.77 |
|
| 2005 |
Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia (New York, N.Y.). 7: 816-23. PMID 16229804 DOI: 10.1593/Neo.05250 |
0.799 |
|
| 2005 |
Faith D, Han S, Lee DK, Friedl A, Hicks JL, De Marzo AM, Jarrard DF. p16 is upregulated in proliferative inflammatory atrophy of the prostate Prostate. 65: 73-82. PMID 15880529 DOI: 10.1002/Pros.20258 |
0.547 |
|
| 2005 |
Schwarze SR, Luo J, Isaacs WB, Jarrard DF. Modulation of CXCL14 (BRAK) expression in prostate cancer. The Prostate. 64: 67-74. PMID 15651028 DOI: 10.1002/Pros.20215 |
0.54 |
|
| 2005 |
Jarrard DF. Does zinc supplementation increase the risk of prostate cancer? Archives of Ophthalmology (Chicago, Ill. : 1960). 123: 102-3. PMID 15642820 DOI: 10.1001/Archopht.123.1.102 |
0.564 |
|
| 2005 |
Kibei AS, Kattan MW, Picus J, Dreicer R, Klein EA, Wilding G, Jarrard DF, Roth B, Cookson MS, Petrylak DP, Ghatta G, Nelson JB, Beer TM, Dipaola R, Partin AW, et al. 1589: Adjuvant Weekly Docetaxel for High-Risk Prostate Cancer Patients After Radical Prostatectomy The Journal of Urology. 173: 222-222. DOI: 10.1016/S0022-5347(18)33781-9 |
0.539 |
|
| 2004 |
Ritter MA, Gilchrist KW, Jarrard DF, Verhoven BM. Integrating biomarkers into clinical predictive and prognostic paradigms for prostate cancer: The role of p53 status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 9604. PMID 28016190 DOI: 10.1200/Jco.2004.22.90140.9604 |
0.379 |
|
| 2004 |
Fu VX, Schwarze SR, Kenowski ML, Leblanc S, Svaren J, Jarrard DF. A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. The Journal of Biological Chemistry. 279: 52218-26. PMID 15471867 DOI: 10.1074/Jbc.M405015200 |
0.424 |
|
| 2004 |
Jarrard DF, Schwarze SR, Fu V, Wilding G, Church D, Brummel S. 1453: The Induction of Cellular Senescence During Therapy for Advanced Prostate Cancer Journal of Urology. 171: 382-383. DOI: 10.1016/S0022-5347(18)38678-6 |
0.563 |
|
| 2004 |
Schwarze SR, Isaacs WB, Oberley TO, Jarrard DF. 587: Cxcl14 (BRAK) Expression is Elevated in Prostate Cancer and May Promote Tumor Progression Through Inflammation and Endothelial Cell Recruitment Journal of Urology. 171: 156-156. DOI: 10.1016/S0022-5347(18)37849-2 |
0.53 |
|
| 2004 |
Allen G, Howard A, Jarrard D, Ritter M. Salvage brachytherapy for locally recurrent prostate cancer after definitive external beam radiation therapy International Journal of Radiation Oncology*Biology*Physics. 60: S475. DOI: 10.1016/J.Ijrobp.2004.07.395 |
0.478 |
|
| 2003 |
Schwarze SR, Fu VX, Jarrard DF. Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. Cancer Research. 63: 4614-9. PMID 12907640 |
0.443 |
|
| 2003 |
Bradley K, Chappell R, Yuan Z, Odau H, Bruskewitz R, Jarrard D, Ritter M. Erectile dysfunction and prostate brachytherapy doses to the penile bulb and neurovascular bundles International Journal of Radiation Oncology*Biology*Physics. 57: S399-S400. DOI: 10.1016/S0360-3016(03)01330-0 |
0.454 |
|
| 2002 |
Jarrard DF, Modder J, Fadden P, Fu V, Sebree L, Heisey D, Schwarze SR, Friedl A. Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Letters. 185: 191-9. PMID 12169393 DOI: 10.1016/S0304-3835(02)00282-3 |
0.501 |
|
| 2002 |
Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, Jarrard DF. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. The Journal of Biological Chemistry. 277: 14877-83. PMID 11836256 DOI: 10.1074/Jbc.M200373200 |
0.479 |
|
| 2001 |
Schwarze SR, Shi Y, Fu VX, Watson PA, Jarrard DF. Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene. 20: 8184-92. PMID 11781834 DOI: 10.1038/Sj.Onc.1205049 |
0.394 |
|
| 2000 |
Reznikoff CA, Sarkar S, Jülicher KP, Burger MS, Puthenveettil JA, Jarrard DF, Newton MA. Genetic alterations and biological pathways in human bladder cancer pathogenesis Urologic Oncology-Seminars and Original Investigations. 5: 191-203. PMID 10973707 DOI: 10.1016/S1078-1439(00)00079-X |
0.398 |
|
| 2000 |
Jarrard DF. Editorial: More Data On Locally Extensive Prostate Cancer—Betting On The Margin The Journal of Urology. 163: 1189-1190. PMID 10737492 DOI: 10.1016/S0022-5347(05)67719-1 |
0.482 |
|
| 1999 |
Jarrard D, Yeager T, Shi Y, Kinoshita H, Sarkar S, Meisner L, Resnikoff C, Magrane G. OVERCOMING SENESCENCE REQUIRES ALTERATIONS IN THE p16/pRb PATHWAY IN PROSTATE EPITHELIAL CELLS The Journal of Urology. 124. DOI: 10.1097/00005392-199904010-00498 |
0.486 |
|
| 1999 |
Kinoshita H, Shi Y, Sandefur C, Chang C, Jarrard DF, Herman JG, Bova GS, Isaacs WB. METHYLATION OF THE ANDROGEN RECEPTOR PROMOTER CpG ISLAND IS ASSOCIATED WITH LOSS OF ANDROGEN RECEPTOR (AR) EXPRESSION IN PROSTATE CANCER CELLS The Journal of Urology. 63. DOI: 10.1097/00005392-199904010-00253 |
0.497 |
|
| 1999 |
Jarrard DF. New Perspectives in Prostate CancerBelldegrunA., KirbyR.S. and OliverR.T.D.: New Perspectives in Prostate Cancer. Oxford: Isis Medical Media, Ltd.1998. 423 pages. Journal of Urology. 161: 1424-1425. DOI: 10.1016/S0022-5347(01)61758-0 |
0.498 |
|
| 1998 |
Yeager TR, DeVries S, Jarrard DF, Kao C, Nakada SY, Moon TD, Bruskewitz R, Stadler WM, Meisner LF, Gilchrist KW, Newton MA, Waldman FM, Reznikoff CA. Overcoming cellular senescence in human cancer pathogenesis. Genes & Development. 12: 163-74. PMID 9436977 DOI: 10.1101/Gad.12.2.163 |
0.314 |
|
| 1997 |
Paul R, Ewing CM, Jarrard DF, Isaacs WB. The cadherin cell-cell adhesion pathway in prostate cancer progression. British Journal of Urology. 37-43. PMID 9088271 DOI: 10.1111/J.1464-410X.1997.Tb00799.X |
0.354 |
|
| 1995 |
Jarrard DF, Chodak GW. Prostate cancer staging after radiation utilizing laparoscopic pelvic lymphadenectomy. Urology. 46: 538-41. PMID 7571224 DOI: 10.1016/S0090-4295(99)80268-4 |
0.464 |
|
| 1994 |
Jarrard DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB. Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. The Prostate. 24: 46-53. PMID 8290389 DOI: 10.1002/pros.2990240110 |
0.386 |
|
| Show low-probability matches. |